The DCTH chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the DCTH chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The DCTH stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View DCTH Detailed Price Forecast - CNN Money||View DCTH Detailed Summary - Google Finance|
|View DCTH Detailed Summary - Yahoo! Finance||View DCTH Stock Research & Analysis - Zacks.com|
|View DCTH Trends & Analysis - Trade-Ideas||View DCTH Major Holders - Barrons|
|View DCTH Call Transcripts - NASDAQ||View DCTH Breaking News & Analysis - Seeking Alpha|
|View DCTH Annual Report - CompanySpotlight.com||View DCTH OTC Short Report - OTCShortReport.com|
|View DCTH Fundamentals - TradeKing||View DCTH SEC Filings - Bar Chart|
|View Historical Prices for DCTH - The WSJ||View Performance/Total Return for DCTH - Morningstar|
|View the Analyst Estimates for DCTH - MarketWatch||View the Earnings History for DCTH - CNBC|
|View the DCTH Earnings - StockMarketWatch||View DCTH Buy or Sell Recommendations - MacroAxis|
|View the DCTH Bullish Patterns - American Bulls||View DCTH Short Pain Metrics - ShortPainBot.com|
|View DCTH Stock Mentions - StockTwits||View DCTH Stock Mentions - PennyStockTweets|
|View DCTH Stock Mentions - Twitter||View DCTH Investment Forum News - Investor Hub|
|View DCTH Stock Mentions - Yahoo! Message Board||View DCTH Stock Mentions - Seeking Alpha|
|View Insider Transactions for DCTH - SECform4.com||View Insider Transactions for DCTH - Insider Cow|
|View DCTH Major Holdings Summary - CNBC||View Insider Disclosure for DCTH - OTC Markets|
|View Insider Transactions for DCTH - Yahoo! Finance||View Institutional Holdings for DCTH - NASDAQ|
|View DCTH Stock Insight & Charts - FinViz.com||View DCTH Investment Charts - StockCharts.com|
|View DCTH Stock Overview & Charts - BarChart||View DCTH User Generated Charts - Trading View|
Delcath Joins the Ocular Melanoma Community in Recognizing Rare Disease Day
Posted on Thursday February 28, 2019
Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, highlights the experiences of patients with ocular melanoma as part of Rare Disease Day®—a global awareness campaign observed each year on February 28th. Delcath sponsors a global Registration clinical trial for Patients with Hepatic Dominant Ocular Melanoma called The FOCUS Trial. “Rare Disease Day is an opportunity for the global healthcare community to recognize the unmet medical needs among patients suffering from orphan diseases,” said Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath.
Delcath Announces Health Authority Approval for CHEMOSAT in Brazil
Posted on Monday February 11, 2019
Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company has received medical device approval for the CHEMOSAT® Hepatic Delivery System (CHEMOSAT) from the national health authority in Brazil. The approval of CHEMOSAT as a Class 3 medical device was issued by the Agência Nacional de Vigilância Sanitária (ANVISA), and permits the marketing and utilization of CHEMOSAT under the same percutaneous intra-arterial administration of melphalan hydrochloride to the liver with subsequent extracorporeal filtration of blood indication, as in Europe. To develop Brazilian market access for CHEMOSAT, Delcath intends to align with a local strategic partner.
Delcath Announces Acceptance of Abstract for Oral Presentation at ECIO 2019
Posted on Friday February 08, 2019
Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces an abstract from a prospective phase 2 study conducted in the Netherlands of the use of the Delcath Hepatic CHEMOSAT® Delivery System to treat patients with metastatic ocular melanoma with liver metastases, has been accepted for oral presentation and as a poster at the European Conference on Interventional Oncology (ECIO) annual meeting. The abstract, Percutaneous hepatic perfusion with melphalan in patients with unresectable liver metastases from ocular melanoma using the Delcath System's second-generation hemofiltration system: a prospective phase II study, will be presented by T.S. Meijer and M.C. Burgmans, et al of the Leiden University Medical Center in the Netherlands.
Delcath Announces Commercial Licensing Agreement for CHEMOSAT®
Posted on Wednesday December 26, 2018
Upfront and Milestone Payments Provide Additional Resources to Advance Clinical Development in the U.S. NEW YORK, Dec. 26, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the company has entered into a definitive licensing agreement for CHEMOSAT® commercialization in Europe with medac Gesellschaft für klinische Spezialpräparate mbH (medac), a privately held, multi-national pharmaceutical company based in Hamburg area, Germany. Founded in 1970, medac specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.